Thus, there is a synergistic effect between sorafenib and GANT61, and GANT61 increases sensitivity to sorafenib in CD44-positive HCC cells by decreasing cell viability and inhibiting malignant transformation. This evidence concerns the gene CD44 and hepatocellular carcinoma.